Literature DB >> 17488673

Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018).

Sven Trelle, Orhan Sezer, Ralph Naumann, Mathias Rummel, Ulrich Keller, Andreas Engert, Peter Borchmann.   

Abstract

We conducted a two-stage phase II study to investigate the activity of bortezomib and dexamethasone in patients with relapsed Hodgkin's lymphoma. The study was prematurely closed after the first stage with twelve enrolled patients because no response was observed. A meta-analysis of all four available studies evaluating bortezomib in this population showed no activity of bortezomib (combined response rate: 0.03; 95%-CI: 0.01 to 0.12).

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17488673     DOI： 10.3324/haematol.10797

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  7 in total

1.  Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma.

Authors:  Jitakshi De; Robert E Brown
Journal:  Int J Clin Exp Med       Date:  2010-01-30

2.  A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.

Authors:  Patrick B Johnston; David J Inwards; Joseph P Colgan; Betsy R Laplant; Brian F Kabat; Thomas M Habermann; Ivana N Micallef; Luis F Porrata; Stephen M Ansell; Craig B Reeder; Vivek Roy; Thomas E Witzig
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

Review 3.  Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options.

Authors:  Kevin A David; Lauren Mauro; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2007-10

4.  Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.

Authors:  J H Mendler; J Kelly; S Voci; D Marquis; L Rich; R M Rossi; S H Bernstein; C T Jordan; J Liesveld; R I Fisher; J W Friedberg
Journal:  Ann Oncol       Date:  2008-05-25       Impact factor: 32.976

Review 5.  Novel CD20 monoclonal antibodies for lymphoma therapy.

Authors:  Shundong Cang; Nikhil Mukhi; Kemeng Wang; Delong Liu
Journal:  J Hematol Oncol       Date:  2012-10-11       Impact factor: 17.388

Review 6.  Targeted therapy in lymphoma.

Authors:  Patrick B Johnston; RuiRong Yuan; Franco Cavalli; Thomas E Witzig
Journal:  J Hematol Oncol       Date:  2010-11-23       Impact factor: 17.388

7.  Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.

Authors:  Theodoros Karantanos; Ioannis Politikos; Vassiliki A Boussiotis
Journal:  Blood Lymphat Cancer       Date:  2017-05-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.